Ixazomib for Desensitization (IXADES) in Highly Sensitized Kidney Transplant Candidates: A Phase II Clinical Trial
{{output}}
Key Points: Ixazomib treatment resulted in decreases in B-cell subsets and bone marrow lymphocytes.Ixazomib treatment resulted in modest decreases in certain anti-HLA antibody specificities.Ixazomib treatment was tolerated, with... ...
